Biostem Technologies (BSEM) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $72.53 million, up 73% year-over-year, marking a record quarter and fifth consecutive quarter of profitability.

• GAAP net income was $4.5 million ($0.27 per share), up from $3.3 million ($0.20 per share) in Q1 2024.

• Adjusted EBITDA was $7.8 million, nearly flat year-over-year, as higher gross profit was offset by increased operating expenses.

• Ended the quarter with $26.7 million in cash, up from $22.8 million at year-end 2024.

• Strong commercial momentum for VENDAJE AC and BioRetain-powered products, with national rollout and growing adoption.

Financial highlights

• Net revenue grew to $72.53 million from $41.9 million in Q1 2024, a 73% increase.

• Gross profit was $71.7 million (99% margin), up from $39.7 million (95% margin) in Q1 2024.

• Operating expenses rose to $66.4 million from $35.1 million, reflecting investments in headcount, service fees, R&D, and compensation.

• Operating income for Q1 2025 was $5.25 million, up from $4.61 million in Q1 2024.

• Basic EPS for Q1 2025 was $0.27, up from $0.20 in Q1 2024; diluted EPS was $0.17.

Outlook and guidance

• Focus remains on expanding VENDAJE AC footprint, driving operational efficiencies, advancing clinical validation, and completing NASDAQ uplisting.

• No formal revenue or EBITDA margin guidance provided for 2025; management expects continued variability in sales and earnings.

• Encouraged by LCD implementation date extension to January 2026, reducing near-term reimbursement uncertainty.